Form 4: Director Frissora Boosts Stake in Bioadaptives with Preferred Stock

Bioadaptives Director Mark P. Frissora acquired 2,578 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Director Mark P. Frissora acquired 2,578 shares of Series D Convertible Preferred Stock in Bioadaptives, Inc. (BDPT) on March 1, 2026.
• These shares were issued as compensation for board services, as per a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation.
• Conversion of these preferred shares is restricted for six months from the issuance date, meaning they cannot be converted before September 1, 2026, except in the case of liquidation.
• The Series D Convertible Preferred Stock carries significant voting power, entitling the holder to 100 votes per share on matters of the Issuer, irrespective of the beneficial ownership limitation.
• The right to convert the preferred stock into common stock does not expire.
• Following this transaction, Frissora beneficially owns a total of 62,360 shares of Series D Convertible Preferred Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating a director's increased stake and long-term alignment, though the compensation method itself is standard.

Positives

• Director Mark P. Frissora increased his beneficial ownership in Bioadaptives, Inc. by acquiring 2,578 shares of Series D Convertible Preferred Stock, signaling continued commitment.
• The Series D Convertible Preferred Stock grants significant voting power, with 100 votes per share, enhancing the director's influence in corporate governance.
• The right to convert the preferred stock into common stock does not expire, providing long-term flexibility and potential upside.

Negatives

• Conversion of the Series D Convertible Preferred Stock is subject to a six-month lock-up period from the issuance date (until September 1, 2026), limiting immediate liquidity.
• A 4.9% beneficial ownership limitation applies to the conversion into common stock, which could restrict the full conversion of all preferred shares at once if it exceeds this threshold.

Risks

• The value of the convertible preferred stock is inherently tied to the performance of the underlying common stock, which carries market risks.
• The 4.9% beneficial ownership limitation could impact the director's ability to fully convert their preferred shares into common stock if the total common stock ownership would exceed this threshold, potentially affecting liquidity or control.

Future Outlook

The Series D Convertible Preferred Stock acquired by Director Frissora has no expiration date for conversion, indicating a long-term commitment to the company. However, the six-month conversion restriction and the 4.9% beneficial ownership limitation will influence the timing and extent of future common stock conversions.

Management Comments

• "Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person."
• "The Reporting Person's shares of Series D Convertible Preferred Stock... are convertible into shares of common stock... at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation."
• "No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately."
• "Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation."
• "The right to convert does not expire."

Industry Context

StockSavvy.ai notes that the issuance of convertible preferred stock as compensation is a common practice, particularly in smaller or growth-stage companies, allowing them to conserve cash while aligning director incentives with long-term shareholder value. This move by Bioadaptives suggests a strategic approach to executive compensation, leveraging equity rather than immediate cash outflows.

Comparison to Industry Standards

• Issuing convertible preferred stock as compensation is a standard practice, similar to how many biotech startups or early-stage tech companies compensate directors or key executives to preserve cash. For example, companies like Moderna in its early stages or smaller biotechs often use equity-based compensation.
• The 100:1 conversion ratio and 100 votes per preferred share are specific to Bioadaptives' capital structure and governance, making direct comparisons difficult without knowing the specific preferred stock terms of other companies. However, high voting rights for preferred shares are common in dual-class structures or for strategic investors.
• The six-month lock-up period for conversion is a typical vesting or holding period seen in many equity compensation plans across various industries, aiming to align long-term interests.

Corporate Governance

Related Party Transactions

• Issuance of 2,578 shares of Series D Convertible Preferred Stock to Director Mark P. Frissora as compensation for board services, as per a Board of Directors Agreement dated February 3, 2025.

Stakeholder Impact

• Shareholders: Potential future dilution upon conversion of preferred stock into common stock, but also increased alignment of director's interests. The high voting power of preferred shares could concentrate control.
• Director (Mark P. Frissora): Increased equity stake and voting power in the company, aligning his financial interests with the company's long-term performance.

Next Steps

• The Series D Convertible Preferred Stock will become convertible into common stock on or after September 1, 2026.
• The director may choose to convert the preferred stock into common stock at any time after the six-month restriction, subject to the 4.9% beneficial ownership limitation.

Key Dates

Recommendation

This Form 4 filing reports a routine compensation event for a director, involving the issuance of convertible preferred stock. While it indicates continued director alignment and commitment, it does not present new information that would fundamentally alter the company's valuation or strategic outlook to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future operational and financial reports for more substantive insights.

Keywords

BIOADAPTIVES, BDPT, Form 4, Insider Transaction, Director Compensation, Convertible Preferred Stock, Beneficial Ownership, Mark P. Frissora, Corporate Governance